Preliminary evidence on the safety of ICSI with testicular spermatozoa in HCV-infected male: a case report.
An infertile couple with a hepatitis C (HCV) RNA-positive male came to our attention. We were not able to perform an assisted reproduction technology (ART) procedure with ejaculated spermatozoa free of HCV RNA using gradient centrifugation and swim up, due to retrograde ejaculation and severe male factor. ICSI with testicular spermatozoa was the most rational therapeutic approach. The couple was informed about the lack of adequate data on the safety of this therapeutic approach. The risks of this procedure were accepted by the couple. Testicular sperm aspiration combined with ICSI (TESA-ICSI) was performed. After a negative result for an HCV RNA PCR on the embryos' culture medium, four embryos were transferred to the uterine cavity on the third day. The procedure resulted in an ongoing clinical pregnancy, and HCV antibody determinations performed in the mother at the 12th and 24th week of pregnancy were negative. The pregnancy ended at the 39th week due to endo-uterine death. No malformation or hepatic pathologies were found in the conceptus. A second TESA-ICSI cycle is ongoing. This preliminary evidence suggests that, in HCV sero-positive males, ICSI with testicular spermatozoa may be a safe procedure. However, we need more observations to clarify if ART is really able to reduce horizontal and vertical transmission of HCV in sero-discordant couples (only the male infected) in comparison with natural conception.
Manno
M
M
Service of Physiopathology of Human Reproduction, Obstetrics and Gynaecology Unit, Maternal-Paediatric Department, Pordenone Hospital, Italy. serpma@aopn.fvg.it
Marchesan
E
E
Crovatto
M
M
Martelli
P
P
Tomei
F
F
Adamo
V
V
D005260:Female; D006526:Hepatitis C / Q000150:complications* / Q000517:prevention & control / Q000635:transmission; D006801:Humans; D007248:Infertility, Male / Q000150:complications* / Q000473:pathology / Q000628:therapy*; D008297:Male; D011247:Pregnancy; D012449:Safety; D020554:Sperm Injections, Intracytoplasmic / Q000009:adverse effects / Q000379:methods*; D013737:Testis / Q000473:pathology